Developing differentiated therapies that can improve the health of patients with liver and gastrointestinal (GI) diseases

NASH is expected to become the leading cause for liver transplants in the United States.

Inflammatory bowel disease is increasing in prevalence worldwide

Metacrine is building a pipeline of potential best-in-class FXR agonist therapeuties for NASH and other GI diseases

Our Company

We are a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and GI diseases.

Latest News

January 19, 2021

Metacrine Announces FDA Fast Track Designation for MET642 as a Treatment of NASH

January 05, 2021

Metacrine Initiates Phase 2a Combination Trial of MET409 with Empagliflozin in Patients with Type 2 Diabetes and NASH

Programs

Our most advanced program targets the farnesoid X receptor, or FXR, which is central to modulating liver and GI diseases.